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MD-2 is a part of the Toll-like 4 signaling complex with an
indispensable role in activation of the lipopolysaccharide (LPS)
signaling pathway and thus a suitable target for the therapeutic
inhibition of TLR4 signaling. Elucidation of MD-2 structure
provides a foundation for rational design of inhibitors that bind
toMD-2 and inhibit LPS signaling. Since the hydrophobic bind-
ing pocket of MD-2 provides little specificity for inhibitors, we
have investigated targeting the solvent-accessible cysteine resi-
due within the hydrophobic binding pocket of MD-2. Com-
pounds with affinity for the hydrophobic pocket that contain a
thiol-reactive group, which mediates covalent bond formation
with the free cysteine residue ofMD-2, were tested. Fluorescent
compounds 2-(4-(iodoacetamido)anilino)naphthalene-6-sul-
fonic acid andN-pyrenemaleimide formed a covalent bondwith
MD-2 through Cys133 and inhibited LPS signaling. Cell activa-
tion was also inhibited by thiol-reactive compounds JTT-705
originally targeted against cholesterol ester transfer protein and
antirheumatic compound auranofin.Oral intake of JTT-705 sig-
nificantly inhibited endotoxin-triggered tumor necrosis factor
 production in mice. The thiol group of MD-2 also represents
the target of environmental or endogenous thiol-reactive com-
pounds that are produced in inflammation.
TLR4 is a receptor for lipopolysaccharide (LPS)4 a major
constituent of outer membrane of Gram-negative bacteria.
MD-2 is the final LPS-binding protein in the recognition cas-
cade beforeTLR4 transmits the signal across the cellmembrane
to activate the inflammatory response. MD-2 binds to the
ectodomain of TLR4 and binds LPS either alone or in complex
with TLR4 (1, 2). Mice deficient in MD-2 survive endotoxic
shock (3). MD-2 has been indispensable in almost all investi-
gated conditions of TLR4-triggered inflammation; therefore, it
could represent the “Achilles’ heel” of the inflammatory
response to LPS and a target for a pharmacological intervention
in endotoxemia as well as other conditions involving cell acti-
vation mediated by TLR4 (4, 5). The existence of a single free
cysteine residue among the seven cysteine residues has been
predicted fromMD-2mutagenesis (6, 7) andmolecular model-
ing proposed that Cys133 lies in the hydrophobic pocket (8, 9).
The hydrophobic binding site of MD-2 was also mapped by an
apolar probe, bis-ANS, which does not contain acyl chains as
most LPS antagonists yet preserves the characteristic structural
motif of lipidA, consisting of a hydrophobic region and a pair of
separated negatively charged groups (10). Crystal structures of
MD-2 with bound eritoran or lipid IVa confirmed the location
of Cys133 in the hydrophobic pocket in close vicinity of bound
lipid A derivatives (11, 12). The free cysteine residue inside the
binding pocket can thus be a target for irreversible inhibition of
MD-2 activity. An inhibitory mechanism based on a covalent
modification of a free cysteine residue in the active or binding
site of a protein has been demonstrated for other proteins, such
as in cysteine proteases, where the cysteine residue participates
in the catalytic triad (13), in cholesteryl ester transfer protein
(CETP) (14), IB kinase (15), thioredoxin reductase (16), and
sortase (17).
In our study, we investigated the possibility of targeting free
cysteine residue ofMD-2 for the inhibition of LPS signaling.We
determined covalent binding into the hydrophobic pocket of
MD-2 for fluorescent compounds 2-(4-(iodoacetamido)ani-
lino) naphthalene-6-sulfonic acid (IAANS) andN-pyrenemale-
imide. Drugs JTT-705 and auranofin, already in use for alterna-
tive indications, were also shown to bind toMD-2 and decrease
LPS signaling. The identity of Cys133 as the residue responsible
for this interaction was demonstrated by point mutagenesis.
Our results confirm that the proposedmechanism of inhibition
ofMD-2 can have potential therapeutic value butmay also have
a physiological role.
MATERIALS ANDMETHODS
Reagents—LPS (from Salmonella abortus equi HL83) was
prepared by a phenol extraction procedure and was kindly pro-
vided by Dr. Brandenburg (Forschungszentrum Borstel, Ger-
many). Another type of LPS used in animal experiments, the
smooth LPS of Pseudomonas aeruginosa PAO1 was obtained
from the aqueous phase of a water-phenol extract and purified
by treatment with chaotropic agents and detergents according
to published procedures (18, 19). To ensure appropriate
homogenization, purified LPS was subjected to three consecu-
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tive cycles of heating (15 min at 56 °C) and cooling (5 min on
ice) before use. The following compounds were tested: IAANS
and N-(1-pyrene) maleimide from Molecular Probes (The
Netherlands), JTT-705 from Cayman chemical (Ann Arbor,
MI), and auranofin from Alexis Biochemicals (San Diego, CA).
Iodoacetamide was purchased from Sigma. Chicken anti-hu-
manMD-2 polyclonal antibodieswere prepared against recom-
binant human MD-2 by GenTel (Madison, WI), monoclonal
mouse anti-human MD-2 9B4 antibodies were ordered from
eBioscience (San Diego, CA), and secondary goat anti-mouse
IgG antibodies conjugated with horseradish peroxidase were
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Cell Lines—Human embryonic kidney 293 and 293T
(HEK293 and HEK293T) cells were cultured as an adherent
monolayer at 37 °C, 5% CO2, and normal humidity in Dulbec-
co’s modified Eagle’s medium (Invitrogen) supplemented with
10% (v/v) fetal bovine serum (BioWhittaker,Walkersville,MD).
Mouse macrophages RAW264.7 were cultured as suspension
cells in RPMI 1640 (Invitrogen) supplemented with 12% (v/v)
fetal bovine serum (BioWhittaker).
Site-directed Mutagenesis—A specific point mutation was
introduced into plasmid pET14b human MD-2 using site-
directedmutagenesis. A site-directedmutagenesis kit (Strat-
agene, La Jolla, CA) was used, and the reaction was per-
formed according to the manufacturer’s instructions. The
sequences of primers used to change the amino acid residue
Cys133 to Phewere 5-AAATTTTCTAAGGGAAAATACAAA-
TTTGTTGTTGAAGCTATTTCTGGGAG-3 and 5-CTCCC-
AGAAATAGCTTCAACAACAAATTTGTATTTTCCCTT-
AGAAAATTT-3. The complete sequence ofMD-2mutantwas
verified by DNA sequencing.
Preparation of Recombinant MD-2 WT and MD-2C133F—
Recombinant MD-2 was produced in Escherichia coli as
described previously (8), using solubilization of inclusion bod-
ies followed by their purification and refolding on reversed
phase columnchromatography. Biological activity ofMD-2was
tested on HEK293 cells transfected with TLR4.
Fluorescence Measurements—Fluorescence measurements
were performedwith an LS55 spectrofluorimeter (PerkinElmer
Life Sciences) with a double monochromator. All measure-
ments were done in 10 mM Tris-HCl buffer, pH 7.5, at 25 °C in
a 5 5-mm quartz cell. A slit width of 5 nm was used for both
excitation and emission. MD-2WT orMD-2C133F (1 M) was
added to 5 M compound solution. Binding of fluorescent
IAANS andN-pyrene maleimide to MD-2 was measured using
an excitation wavelength of 326 and 338 nm, respectively. Dis-
placement of fluorescent probe bis-ANSwas used to determine
binding of nonfluorescent auranofin to MD-2. 1 M bis-ANS
and 1 M MD-2 were mixed and incubated to reach stable flu-
orescence at an excitationwavelength of 380 nm. Then aurano-
fin was added in 2 M increments, and decrease of the initial
emission fluorescence was followed.
Determination of Covalent Interaction between MD-2 and
Synthetic Compound N-Pyrene Maleimide—Distribution of
N-pyrene maleimide between the aqueous and organic phase
was determined by extraction with chloroform. 1 volume of
N-pyrenemaleimide (40M) in 10mMTris-HCl buffer, pH 7.5,
was extracted with 2 volumes of chloroform. The extraction
was repeated twice. Afterward, the content of N-pyrene male-
imide in aqueous and organic phase was determined by fluores-
cence measurement at an excitation wavelength of 338 nm.
MD-2 (10 M) was added to the aqueous solution of N-pyrene
maleimide and incubated for 2 h at 25 °C. As a control, either
MD-2 WT, which was preincubated with 50 M of iodoacet-
amide to block free cysteine residues, or a mutant MD-2C133F
was used in the reaction. The requirement for the native con-
formation and formation of a covalent bond betweenN-pyrene
maleimide andMD-2was analyzed by the addition of guanidine
HCl (6 M) to the mixture of MD-2 with N-pyrene maleimide
after previous preincubation and followed by chloroform
extraction as described above. The extraction removed
unbound and noncovalently bound compound. The complex
was then precipitatedwith 5 volumes of ice-cold acetone for 1 h
at20 °C and centrifuged. Acetone was removed, and the pel-
let waswashedwith acetone. The pellet was then resolved in 6M
guanidine HCl, and the fluorescence spectra of samples were
measured.
ELISA—AnELISAwas used to determine binding of selected
compounds to MD-2. Polyclonal chicken anti-human MD-2
antibodies in 50 mM Na2CO3, pH 9.6, were used to coat a
96-well microtiter plate. The plate was incubated overnight at
4 °C and then rinsed with phosphate-buffered saline. Excess
binding sites were blocked with 1% bovine serum albumin
(Sigma) in phosphate-buffered saline buffer. 1MMD-2WT in
10 mM Tris-HCl buffer, pH 7.5, was preincubated with IAANS,
N-pyrenemaleimide, JTT-705, or auranofin in the range from 0
to 20 M for 2 h at 25 °C. As a negative control, compounds
were preincubated in buffer. 200 l/well of preincubated solu-
tions were added into a precoated plate and were incubated for
2 h at 25 °C. After rinsing, MD-2 bound to coated polyclonal
chicken anti-MD-2 antibodies was detected by primary mouse
anti-human MD-2 9B4 monoclonal antibodies, followed by
secondary goat anti-mouse IgG antibodies conjugated with
horseradish peroxidase. Both steps were carried out in phos-
phate-buffered saline for 1.5 h at 37 °C. Horseradish peroxidase
was detected using 2,2-azinobis(3-ethylbenzthiazoline-6-sul-
fonic acid) substrate (Sigma). When color was developed, the
reaction was stopped with 1% SDS, and the absorbance at 420
nm was measured. The compounds were investigated also for
binding to the mutant MD-2C133F by the same procedure.
Measurements of Macrophage Response to LPS and Its
Inhibition—RAW264.7 cells were seeded at 2  105 cells/96-
well in RPMI containing 12% fetal bovine serum and 100 M
PTIO. Individual compound was added and preincubated for
1 h. Cells were then stimulated with 100 ng/ml LPS overnight.
NOwas detected in supernatants using Griess reagent (Sigma).
A standard curve was prepared using sodium nitrite, and
absorbance measurements were converted to concentrations.
Luciferase Reporter Assay—To determine the effect of JTT-
705 and auranofin on the activity of recombinant hMD-2, 2M
hMD-2WTor hMD-2C133Fwasmixed with 0, 40, 100, 200, or
300 M concentrations of compound in 2 mM Tris-HCl buffer,
pH 7.5, to allow thiolate reactivity of a cysteine residue and
incubated for 1 h at room temperature.HEK293 cellswere tran-
siently transfected with hTLR4 expression vector as well as NF-
B-dependent luciferase and constitutiveRenilla reporter plas-
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mids. 6 h later, transfection media were changed, and 5 l of
MD-2JTT-705 complex was added per well to reach 100 nM
final concentration ofMD-2. After 1 h of incubation, cells were
stimulated with 100 ng/ml LPS. After 16 h, cells were lysed and
analyzed for reporter gene activities using a dual luciferase
reporter assay system on a Mithras LB940 luminometer. Data
from luciferase activity were normalized using Renilla lucifer-
ase readings. Inhibition of the MyD88-dependent signaling
pathway was determined by transfecting HEK293T cells with 3
ng of MyD88 expression vector and NF-B-dependent lucifer-
ase reporter plasmids. 6 h later, transfection medium was
changed followed by the addition of JTT-705 or auranofin and
incubated for 16 h. Cells were lysed and analyzed for luciferase
activity as described above.
Animal Experiment—Mouse feed pellets containing JTT-705
weremade by first mixing 50mg of the compoundwith 300 g of
powdered mouse feed (Harlan) using an electric food blender.
Then 75 ml of a 5% solution of cornstarch was added to the
mixture, and the suspension was thoroughly homogenized in
the food mixer, divided into pellets, and dehydrated in a glass-
ware air dryer. Female C57BL/6J mice weighing 13–16 g were
purchased from Harlan Spain (Harlan Interfauna Iberica S.A.,
Barcelona, Spain) and randomly distributed in experimental
groups (n  8). Animals provided with JTT-705-containing
pellets ate their feed at the same rate (4 g/day, approximately) as
animals fed regular mouse feed, and all mice had a similar
weight at the end of the feeding period. 6 days after the begin-
ning of the treatment, animals received an intraperitoneal
injection containing a mixture of 50 ng of LPS and 18 mg of
D-galactosamine resuspended in 200l of endotoxin-free saline
following the method of Galanos et al. (20). In previous exper-
iments, this dose of LPS-galactosamine killed 90–100% of the
animals 48 h postinoculation. As a positive control of protec-
tion against endotoxic shock, mice from one of the groups fed
regular mouse pellets received 150 l of pyrogen-free saline
containing 150g of polymyxinB (PMB) immediately after LPS
challenge. To facilitate the therapeutic action of PMB, mice
were gently massaged at the site of inoculation for a few sec-
onds. Animalmortality wasmonitored at 6 and 12 h postinocu-
lation and at daily intervals for 5 days. In separate experiments,
serum levels of TNF were determined in the animal groups
(n 4) at 60 min postinoculation coinciding with the cytokine
peak production as established in previous experiments. For
that purpose, mice were anesthetized, a sample of blood was
obtained by cardiac puncture, and serum levels of TNF were
quantified using the Quantikine TNF immunoassay kit (R&D
Systems, Minneapolis, MI) following the manufacturer’s
instructions. All of the animal protocols used in this study were
approved by the University of Navarra Animal Research Com-
mittee (protocol number 035/05).
Molecular Docking—The coordinates of human MD-2 (Pro-
tein Data Bank code 2E59) and models of compounds created
by geometry minimization using Chemscape were used for
docking calculations with AutoDock. Protein was kept rigid,
whereas in the ligands 1–4 bonds were flexible, producing 100
docked structures.
RESULTS
Selection of Compounds with Potential Inhibitory Effect on
MD-2—Crystal structure of MD-2 in complex with the tet-
raacylated antagonists lipid IVa and eritoran clearly identified
the binding site for lipid A derivatives (11, 12). Most contacts
between the protein and a ligand are achieved through hydro-
phobic interactions between hydrophobic residues of MD-2
and fatty acid chains of lipid A. Polar interactions are involved
in a relatively low number of contacts. A single free cysteine
residue (Cys133) is conserved in allMD-2 orthologues but not in
the MD-1 family, which does not bind LPS or activate LPS sig-
naling (10). Cys133 lies inside the hydrophobic binding pocket
and is exposed to solvent (Fig. 1A). Its replacement with hydro-
phobic residues retains the functional activity of MD-2 (6, 10).
Due to the structural considerations described above, we antic-
ipated that compounds comprising both the cysteine-reactive
group and large hydrophobic moiety could increase the selec-
tivity for targeting MD-2 and thus more effectively inhibit the
LPS signaling pathway. We predicted that this type of interac-
tion with MD-2 should prevent LPS binding. To test this
hypothesis, we selected four compounds with the above men-
tioned requirements (Fig. 1B). Two of the compounds, IAANS
andN-pyrenemaleimide, were selected among the intrinsically
fluorescent thiol-reactive compounds, whose binding to MD-2
could bemonitored by fluorescence. Both fluorophores contain
a bulky lipophilic moiety, which contributes to the binding
energy and leads the thiol-reactive compound toward its target.
Additionally, IAANS contains the ANS group, for which we
previously showed high affinity for MD-2 (10). Two further
compounds that comply with the set of desired structural
motifs were selected among the drugs that are in clinical use or
in clinical studies for different indications and whose literature
data suggested immunosuppression of LPS stimulation (21, 22).
Thioester JTT-705 has been developed as an inhibitor of CETP
(14). CETP contains a free cysteine residue within a pocket
where cholesteryl ester binds and therefore in many ways pos-
sesses structural properties resembling those of the MD-2
pocket. The second tested compound was auranofin, which is
used as an anti-rheumatic drug. Auranofin is a gold-containing
compound with sulfur-linked organic ligands. Au(I) has thiol
reactivity, and proteins with free cysteine residues represent its
potential targets (23).
Binding of Thiol-reactive Compounds to MD-2—IAANS and
N-pyrene maleimide are fluorescent probes, and their fluores-
cence increases in nonpolar environment, such as organic sol-
vent or upon binding to protein hydrophobic sites. Fluores-
cence of both IAANS (Fig. 2A) and N-pyrene maleimide (Fig.
2B) increased significantly by the addition ofWTMD-2. Signif-
icantly lower fluorescence increase was measured by the addi-
tion ofMD-2C133F. The remaining interaction is probably due
to the noncovalent reversible binding of the probe to MD-2
mutant. Binding of auranofin could not be determined through
direct fluorescence, since the compounddoes not posses intrin-
sic fluorescence. Therefore, we used a competition displace-
ment assay with bis-ANS as before to determine competition
with LPS (10). The gradual addition of auranofin to the bis-
ANSMD-2 complex displaced bis-ANS from MD-2, causing a
Free Thiol Group ofMD-2
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decrease of fluorescence (Fig. 2C), as expected for its binding to
MD-2.
Covalent Binding of N-Pyrene Maleimide to MD-2—N-Py-
rene maleimide contains a maleimide group that can form a
thioester with free thiol-containing polypeptides. We have
therefore tested our hypothesis thatN-pyrenemaleimide forms
a covalent bond withMD-2 using extraction ofN-pyrenemale-
imide into the organic solvent. Essentially all of the reagent
transferred from the aqueous into the organic phase. The addi-
tion of WT MD-2, MD-2C133F mutant, or WT MD-2 with
blocked free thiol group retained a significant amount ofN-py-
rene maleimide in the aqueous phase (Fig. 3A), which can be
attributed to the affinity ofN-pyrenemaleimide for the binding
site onMD-2. Chemical unfolding of protein should disrupt the
binding site and release the noncovalently bound fluorophore,
whereas the covalently bound compound, on the other hand,
should remain with the protein in the aqueous phase. Fig. 3B
shows that unfolding of WTMD-2 by the addition of 6 M gua-
nidine HCl, subsequent to the formation of a MD-2N-pyrene
maleimide complex, indeed retained N-pyrene maleimide in
the aqueous phase after extraction, demonstrating the forma-
tion of a covalent bond. In the case of the C133F mutant or
when the thiol group of WT MD-2 was carboxymethylated,
complete transfer of N-pyrene maleimide into the organic
phase occurred from the denatured protein solution.
Binding of Thiol-reactive Compounds on MD-2 Overlaps with
the LPS-binding Site and Inhibits Cell Signaling—We expected
that the binding site for IAANS, N-pyrene maleimide, JTT-705,
and auranofin on MD-2 would overlap with the binding site for
LPS. To test this experimentally, we performed an ELISA type of
assay where detection of MD-2compound complex was carried
out with anti-MD-2 monoclonal antibody. Since its binding to
MD-2 is inhibited by LPS (24), occupation of the LPS-binding site
by thecompoundscouldalsoprevent recognitionbyantibody.We
demonstrated that all testedcompoundsboundtoMD-2 inhibited
binding in a concentration-dependent manner but less efficiently
than LPS (Fig. 4). Inhibition of antibody binding due to the com-
petitionwith the investigated compoundwasmaximal for IAANS
(45%), followed by the N-pyrene maleimide (35%), auranofin
(32%), and JTT-705 (30%).Wemayascribe lower inhibitorycapac-
ity of compounds to their smaller size and affinity.Wedetermined
that lipid A inhibited antibody binding at 40% of the LPS value,
which is probably due to the steric effects of the carbohydrates of
the LPS. Based on those results, we further expected that binding
of compounds to MD-2 would prevent LPS activation of macro-
phages.Wedemonstrated that IAANS,N-pyrenemaleimide, JTT-
705, and auranofin inhibit LPS stimulated NO production in
mouse RAW264.7 macrophages (Fig. 5). The most efficient com-
pounds were auranofin andN-pyrene maleimide with IC50 lower
than 1M, whereas JTT-705 and IAANS achieved 50% inhibition
FIGURE 1. Free cysteine residue is positionedwithin the binding pocket of MD-2, which can react with thiol-reactive compounds. Left, MD-2 structure
reveals an internal hydrophobic cavity with a cysteine residue 133 (van derWaals radii shown in yellow), which is located inside the cavity near the bound lipid
IVa antagonist and presents a target for compounds with a thiol-reactive group. Bottom, surface representation of MD-2 with docked pyrene-maleimide
molecules. Right image, MD-2 with covalently bound pyrene-maleimide, indicating steric overlap with bound lipid IVa. Right, tested compounds comprising a
hydrophobic moiety and a thiol-reactive group. N-Pyrene maleimide and IAANS were used as fluorescent probes, whereas JTT-705 and auranofin are drugs
already used in therapy or in clinical trials.
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above 30M. Since auranofin has beendescribed as an inhibitor of
TLR4 dimerization and theMyD88-dependent signaling pathway
(22), inhibition ofNOproduction could be due to the inhibition of
downstream signaling. An additional experiment was performed,
whereMyD88was overexpressed inHEK293T cells to investigate
the potential inhibition downstream of MyD88. Auranofin and
partially JTT-705 inhibitedNF-B activation induced by the over-
expression of MyD88; however, 5 M auranofin was required to
significantly inhibit NF-B activation (Fig. 6). On the other hand,
FIGURE 3.N-Pyrenemaleimide covalently binds toMD-2WT. Extraction of
N-pyrene maleimide from the aqueous phase into the organic phase deter-
mines binding of N-pyrene maleimide to MD-2. A, N-pyrene maleimide was
completely extracted from the buffer to chloroform. Preincubation of MD-2,
eitherWT orWT treatedwith iodoacetamide ormutant C133F, withN-pyrene
maleimide and subsequent extraction retained some N-pyrenemaleimide in
the aqueous phase as a result of tight binding. B, disruption of tertiary struc-
ture of MD-2 by the addition of a chemical denaturant guanidine HCl (6 M)
before the extraction caused the removal of noncovalently bound N-pyrene
maleimide fromtheaqueousphase. Fluorescence intensities arepresented in
relative units (r. u.).
FIGURE 4. Binding site of tested compounds on MD-2 overlaps with the
LPS-binding site. Sandwich ELISA shows competition of compound and LPS
for the samebinding site onMD-2. Recombinant hMD-2WT and IAANS,N-py-
rene maleimide, JTT-705, or auranofin was preincubated to allow the forma-
tion of complex and added to the chicken anti-MD-2 polyclonal antibody-
coated plate. Detection of complex bound to polyclonal antibody was
achieved by anti-MD-2 9B4 monoclonal antibody, which recognizes only
LPS-free MD-2. Compound bound to MD-2 prevented 9B4 binding in a
concentration-dependent manner.
FIGURE 2.Compounds interactwithMD-2 in solution. The addition of 1M
MD-2 to 5M tested compound solution increases the fluorescence emission
ofhydrophobicprobes IAANS (A) andN-pyrenemaleimide (B).C, replacement
of a fluorescent probebis-ANSbound toMD-2with nonfluorescent auranofin
is reflected in a decrease of bis-ANS fluorescence emission. A–C, interaction
betweenMD-2 and IAANS or N-pyrenemaleimide or auranofin is impaired in
mutant MD-2C133F. Fluorescence intensities are presented in relative units
(r. u.) or a percentage (%) of maximal fluorescence intensity.
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already 2 M auranofin completely inhibited LPS-induced NO
production (Fig. 5), showing that the major inhibition target is
located upstream ofMyD88.
Inhibition of LPS Signaling by JTT-705 on Cell Lines and in
Vivo—In order to show that JTT-705 acts through the same
mechanism asN-pyrenemaleimide via the formation of a cova-
lent bond toCys133, we compared binding of JTT-705 to recom-
binant WT MD-2 and MD-2C133F mutant using the ELISA
procedure as described above. JTT-705 still bound to
MD-2C133F but to a significantly lower extent than to the wild
type protein (Fig. 7A). To demonstrate that mutagenesis of
Cys133 also affects LPS signaling in HEK293 cells, we preincu-
bated recombinant proteins with increasing concentrations of
JTT-705. MD-2JTT-705 or MD-2C133FJTT-705 complexes
were added to HEK293 cells expressing TLR4 and stimulated
with LPS. The inhibitory effect of JTT-705 on LPS signalingwas
onlyminor whenMD-2C133F was applied (Fig. 7B). In the case
of WT MD-2, cell activation was reduced by 50% at 15 M
JTT-705, which is also lower than the concentration necessary
for inhibition of MyD88-induced activation. This finding con-
firms that the efficiency of inhibition depends on the reactivity
of Cys133 residue with JTT-705.
For animal studies, the compound JTT-705 had to be admin-
istered to mice mixed with their feed due to its very low water
solubility (see “Materials and Methods”). Animals were fed
JTT-705-containing mouse pellets for 6 days, and each animal
received an estimated dose of 0.6 mg of compound/day. On a
body weight basis, this dose is 2 times higher than the dose
shown to be effective for inhibiting CETP activity in humans
(25). After the end of the feeding period, animals were intrap-
eritoneally inoculated with LPS from P. aeruginosa PAO1, and
serum levels of TNF were determined 60 min after LPS inoc-
ulation. In addition, animal mortality was monitored daily for
72 h. As the positive control of protection, a duplicate group of
animals fed regular mouse pellets received an intraperitoneal
injection of PMB immediately after LPS challenge. Serum levels
FIGURE 5.Compounds inhibit LPS inducedNOproduction.RAW264.7 cells
were seeded and preincubated with increasing concentrations of N-pyrene
maleimide (top left), IAANS (top right), JTT-705 (bottom left), or auranofin (bot-
tom right) for 1h.After LPS stimulation for 16h, releaseofNO into themedium
was determined using Griess reagent, and the NO amount was calculated
from the standard curve.
FIGURE6.AuranofinandJTT-705 inhibit theMyD88-dependent signaling
pathway. HEK293T cells were transfected with MyD88 and NF-B reporter
plasmids. Afterward, cells were treated with auranofin and JTT-705 for 16 h.
Inhibition of MyD88 overexpression was determined by measuring relative
luciferase activity in cell lysate. *, significantly different from vehicle (p 0.1);
***, significantly different from vehicle (p 0.01).
FIGURE 7. JTT-705 inhibition of LPS signaling depends on the reactivity
with freecysteinegroupofMD-2.A, ELISAconfirmed the importanceof free
Cys133. JTT-705 was preincubated with MD-2 WT or MD-2C133F. JTT-705
bound to MD-2C133F to a lesser extent. Binding of MD-2 without a com-
pound was defined as 100%. B, preincubation of recombinant human MD-2
WT with JTT-705 inhibits LPS-stimulated cell signaling, monitored by the
NF-B-responsive luciferase reporter of TLR4-transfected HEK293. The addi-
tion of preincubated MD-2C133F protein with JTT-705 to TLR4-expressing
HEK293 cells had only minor influence on LPS signaling. **, significantly dif-
ferent from vehicle (p  0.05); ****, significantly different from vehicle (p 
0.005).
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of TNF in animals not treated with JTT-705 were determined
in an independent assay carried out under identical experimen-
tal conditions.
As shown in Fig. 8, treatment with JTT-705 completely abro-
gated LPS-dependent TNF production and resulted in serum
levels of TNF indistinguishable from those measured in the
PMB-treated animals. However, reduction of TNF did not result
in protection against the lethal effects of endotoxic shock, since
groups treated with JTT-705 displayed a mortality at 72 h postin-
oculation similar (90%) to that detected in nontreated animals.
DISCUSSION
Cellular receptor for LPSTLR4plays an important role in infec-
tion as well as in chronic diseases, such as rheumatoid arthritis
(26), atherosclerosis (27, 28), and inflammation caused by tissue
damage (e.g. by ischemia-reperfusion (29) or in hemorrhage-in-
duced acute lung injury (30)). However, efficient inhibitors of
TLR4 activation in inflammatory conditions are not yet in thera-
peutic use, although several of them are at the advanced stages of
clinical trials (31). MD-2, as a component indispensable for LPS-
induced TLR4 signaling, presents amore suitable therapeutic tar-
get for the pharmacological intervention than TLR4. MD-2 is the
targetofLPSantagonists,whichstructurally resemble lipidA, such
asMPLA (32), LPS fromRhodobacter sphaeroidesor tetraacylated
lipid IVa (33), or acyclicderivativesof lipidA(AGP) (34)but alsoof
taxoids in humanMD-2 (35).
Here we demonstrated a new type of inhibitory mechanism
of this important target, which is based on compounds that
combine high affinity for the lipid A-binding hydrophobic
pocket of MD-2 and a thiol-reactive group. We determined
binding of tested compounds to MD-2, formation of covalent
bond, involvement of Cys133 residue ofMD-2, and inhibition of
LPS binding and cell activation as well as proposed additional
therapeutic indications of two drugs in use and in clinical trials,
namely auranofin and JTT-705, respectively. Both auranofin
and JTT-705 have already shown safety in clinical trials.
Auranofin is used in therapy of inflammatory arthritis but less
used due to the side effects. It had been known that auranofin
inhibits LPS-induced interleukin-1 and TNF production (21).
Several possible targets of auranofin have been suggested pre-
viously, such as cysteine proteases of the papain family (36),
IKK (22), andNF-B (37), suggesting that itmay target several
steps in the signaling pathway, although MD-2 has not been
reported to be among them. We achieved almost complete
inhibition of LPS-induced NO production at 2 M auranofin
(Fig. 5). This concentration only minimally decreased the
MyD88-dependent signaling pathway even after 16 h (Fig. 6),
demonstrating the target upstream of MyD88 and the physio-
logical importance of MD-2 as its target. For JTT-705 as an
antihypercholesterolemic compound inhibiting CETP in
humans and rabbits (14), no role in the LPS-induced cell acti-
vation has been reported before. We showed that JTT-705 sig-
nificantly inhibited TNF response to LPS in animals. It was
not effective to preventmortality under those conditions. Addi-
tional inflammatory mediators besides TNF will have to be
analyzed to clarify this discrepancy. Asmuch as 150g of poly-
myxin B had to be administered simultaneously with LPS to the
animals to prevent endotoxin-induced mortality. Polymyxin B
acts further upstream and blocks interaction of endotoxin with
other binding partners in the serum. Neutralization of inflam-
matory mediators of endotoxemia, such as TNF or even
CD14, failed in clinical trials. It has been proposed (38) that a
better strategy might be to combine the inhibition of comple-
ment with neutralization of CD14 (in our case MD-2), which
could attenuate the uncontrolled inflammatory reaction that
leads to breakdown of homeostasis during sepsis. The inhibi-
tion of TNF production by JTT-755 in our experiments is not
likely to be due to the effect on cholesterol metabolism, since
mice do not have a CETP orthologue. Additional information
on the role of JTT-705 in the inhibition of TLR4-driven inflam-
mation might become available as a “side effect” in ongoing
clinical trials of JTT-705 (also known as R1658).
Further improvement of MD-2 inhibitors based on the
described principles could be achieved by increasing their affin-
ity and specificity of binding into the hydrophobic pocket (e.g.
by the addition of negatively charged groups to interact with
cationic residues at the rim of the MD-2 pocket) (10). We have
demonstrated previously that curcumin inhibits LPS signaling
by binding to MD-2, but in this case, it did not form a covalent
bond with Cys133 (39). However, Youn et al. (40) reported that
cinnamaldehyde suppresses LPS-induced homodimerization
of TLR4. Although the role of MD-2 has not been investigated,
it seems likely that this compound couldmodify the thiol group
of MD-2. Recent publications indicate an additional role of TLR4
receptors in sterile inflammationcausedby acute sterile injury and
other disorders. TLR activation with endogenous agonists could
explain the instances of systemic inflammatory response syn-
drome, although bacterial infection cannot be detected. Several
potential endogenous ligands, especially for TLR4, have already
been identified: heparan sulfate, hyaluronic acid, HMGB-1, etc.
(reviewed in Refs. 41 and 42). Based on their structure, heparan
sulfate and hyaluronic acidmight also requireMD-2 for signaling,
so inhibitors that could inhibit ligand binding to MD-2 may have
FIGURE 8. JTT-705 inhibits TNF production in endotoxin-treated mice.
Mice were treated intraperitoneally with 50 ng of LPS and 18mg of galactos-
amine. As a positive control of protection against endotoxic shock,mice from
one of the groups fed regular mouse pellets received 150 g of PMB imme-
diately after LPS challenge. Micewere treatedwith JTT705 by adding it to the
food pellets 6 days before the LPS treatment. Serum levels of TNF were
determined in the animal groups (n 4) at 60 min postinoculation, coincid-
ing with the cytokine peak production as established in previous
experiments.
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broader application and increase the therapeutic options for treat-
ment of these disorders.
Identification of the covalentmechanism of inhibition suggests
that some endogenous or environmental thiol-reactive com-
pounds could affect the LPS responsiveness by modifications of
MD-2 and could thus act as an additional regulator of biological
activity.Cys133 isno longeraccessible to the solvent in thecomplex
evenwith tetraacylated antagonist (ProteinDataBank code 2E59).
Its thiol group is separated from the acyl groups of bound lipid IVa
by less than 3Å. All docked conformations of investigated ligands
intoMD-2 overlap with bound ligand, indicating that they would
inhibit binding. Recently determined crystal structure of the
TLR4MD-2-RaLPS complex and amodel, based onmutations of
MD-2 and TLR4 demonstrated the occupation of the complete
pocket of MD-2 with acyl chains of the LPS. Therefore, even a
small ligand bound to its thiol group could (43, 44) interfere with
lipidAbinding, particularlywithanagonistic chemotype, that typ-
icallycontains sixacyl chains.Acroleinhasbeenreported to inhibit
the NF-B activation by endotoxin (45), and it has recently been
shown that it suppresses the LPS-induced TLR4 dimerization
upstream of MyD88 (46). Acrolein is an unsaturated aldehyde,
produced by pyrolysis of organic material and present as an envi-
ronmental toxin in fried food as well as in cigarette smoke but is
also produced by myeloperoxidase in the organism at sites of
inflammation (47). Acrolein is highly reactive with thiol groups
and could thus also modify the MD-2 and inhibit its ability to
mediate the LPS signal. Conservation of Cys133 in all members of
theMD-2 family and variability of this residue in otherML super-
family members, including MD-1 homologues, provides further
support for the function of the free cysteine residue in the binding
pocket in the suppression of LPS activation.
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